NCT05831189 - A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2023

Primary Completion Date

January 17, 2025

Study Completion Date

January 17, 2025

Conditions

Clostridium Difficile Infection Recurrence

Interventions

DRUG

RBX2660

RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).

Trial Locations (12)

Ferring Investigational Site, Burke

Ferring Investigational Site, Cleveland

Ferring Investigational Site, Madison

Ferring Investigational Site, Plymouth

Ferring Investigational Site, Rochester

Ferring Investigational Site, Gurnee

Ferring Investigational Site, Shreveport

Ferring Investigational Site, North Little Rock

Ferring Investigational Site, Oklahoma City

Ferring Investigational Site, Idaho Falls

Ferring Investigational Site, Camarillo

Ferring Investigational Site, Hamden